Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.69
-2.0%
$0.58
$0.27
$0.82
$750.28M0.251.95 million shs736,485 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$24.08
-2.9%
$30.95
$18.92
$81.73
$2.79B0.739.48 million shs6.84 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$35.99
-0.6%
$35.00
$26.74
$46.00
$2.79B1.17631,542 shs554,048 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-2.00%-1.23%+26.27%-11.60%+90.22%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-2.94%-5.49%-39.85%-8.89%-63.91%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-0.61%-5.76%-5.86%+13.53%-11.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.69
-2.0%
$0.58
$0.27
$0.82
$750.28M0.251.95 million shs736,485 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$24.08
-2.9%
$30.95
$18.92
$81.73
$2.79B0.739.48 million shs6.84 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$35.99
-0.6%
$35.00
$26.74
$46.00
$2.79B1.17631,542 shs554,048 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-2.00%-1.23%+26.27%-11.60%+90.22%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-2.94%-5.49%-39.85%-8.89%-63.91%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-0.61%-5.76%-5.86%+13.53%-11.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.50263.37% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$53.3048.10% Upside

Current Analyst Ratings Breakdown

Latest ELTP, VKTX, XENE, and MOR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$48.00
9/2/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$55.00
8/19/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$102.00
8/12/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$55.00
8/12/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$57.00 ➝ $55.00
8/12/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$42.00 ➝ $43.00
7/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetStrong-Buy$125.00 ➝ $122.00
7/24/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$31.00 ➝ $38.00
6/25/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$102.00
(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M8.75$0.02 per share40.75$0.05 per share13.70
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$7.90 per shareN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$7.50M370.01N/AN/A$9.90 per share3.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-$4.32M-$0.01N/AN/A-10.26%-9.88%-4.72%11/13/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.53N/AN/AN/AN/A-19.98%-19.38%10/22/2025 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$234.33M-$3.55N/AN/AN/AN/A-38.50%-36.47%11/11/2025 (Estimated)

Latest ELTP, VKTX, XENE, and MOR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q1 2026
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A-$0.01N/A-$0.01N/A$40.21 million
8/11/2025Q2 2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.03-$1.07-$0.04-$1.07N/AN/A
7/23/2025Q2 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.44-$0.58-$0.14-$0.58N/AN/A
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.09
7.23
5.44
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
25.86
25.86
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
15.14
15.14

Institutional Ownership

CompanyInstitutional Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.10%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
4.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion918.58 millionNot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.45 million107.84 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21077.11 million73.97 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.69 -0.01 (-2.00%)
As of 09/15/2025 03:59 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 09/12/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$24.08 -0.73 (-2.94%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$24.12 +0.04 (+0.17%)
As of 09/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$35.99 -0.22 (-0.61%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$36.02 +0.02 (+0.07%)
As of 09/15/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.